Drugs for treating severe hypertension in pregnancy: a network meta‐analysis and trial sequential analysis of randomized clinical trials

Review (51 studies; n= 3236) found no significant differences in number of patients achieving target BP or safety profiles between drugs studied. Trial sequential analysis suggests similar efficacy between nifedipine, hydralazine and labetalol

The following interventions were included in the systematic review:

 

- direct‐acting vasodilators (hydralazine, dihydralazine, diazoxide, glyceryl trinitrate),

- sympatholytics (labetalol, ketanserin and urapidil),

- calcium channel blockers (nicardipine, nifedipine and isradipine),

- prostaglandins/prostaglandin analogues [prostaglandin A1 (PGA1) and epoprostenol],

- centrally acting antihypertensive drug (clonidine),

- angiotensin converting enzyme inhibitor (captopril)

- drug combinations (nifedipine/celastrol, nifedipine/resveratrol and nifedipine/vitamin D).